WHO WE ARE
The Marie Curie Legacy Campaign, pioneered by the ESTRO Cancer Foundation (ECF) and ESTRO, is a global initiative to raise awareness of the benefits of radiotherapy and optimise the provision of radiotherapy in Europe and beyond.
The ECF was launched by ESTRO in 2012. Its ambition is to ensure that every cancer patient has access to appropriate and personalised cancer care. The ECF’s projects are designed to raise awareness and understanding of radiotherapy. It is instrumental in facilitating research and make resulting scientific data accessible and understandable to everyone. For more information, visit: www.mariecurielegacy.org
ESTRO was founded in 1980, ESTRO as a non-profit and scientific organisation that fosters the role of Radiation Oncology in order to improve patients’ care in the multimodality treatment of cancer. With over 7300 members in and outside Europe, ESTRO supports all the Radiation Oncology professionals in their daily practice: Radiation Oncologists, Medical Physicists, Radiobiologists and RTTs (Radiation TherapisTs) and the wider oncology community. ”Radiation oncology. Optimal health for all, together”’ is the ESTRO Vision. To do so, ESTRO promotes innovation, research, and dissemination of science through its congresses, special meetings, educational courses and publications.
The Foundation’s objective is to promote radiation oncology, support professional development, provide medical education, and boost research in the field of radiation oncology.
To ensure that every cancer patient has access to the appropriate and personalised cancer care, the ECF tackles the barriers to an optimal provision of radiotherapy.
Barriers such as lack of resources – in terms of radiotherapy equipment, staff and education – and a lack of knowledge of radiotherapy, contribute to reducing the opportunity for the patients to receive the treatment that best corresponds to their disease, therefore participating to the creation of the gap between the optimal and the current utilisation of radiotherapy in Europe.
To reduce this gap, ECF key areas of actions are:
Creating patient, family, healthcare professionals and community awareness regarding the benefits and importance of radiation oncology is crucial to drive forth its relevance and impact on the treatment of cancer. Decision makers also need to be made aware of the benefits of radiotherapy and its impact on oncology care.
There is a major need for rapid development and uptake of innovative cancer treatments. Radiation oncology is a cornerstone of modern cancer treatment, its impact on survival of cancer – alone or in conjunction with other treatments – is crucial. To help further enhancing the role of radiotherapy as essential part of modern cancer treatment, the ECF aims at the dissemination of research outcomes related to innovative radiation oncology methods and techniques, for the benefit of the patients.
It is estimated that the number of cancer patients in Europe in 2020 will reach around 3 million, more than 50% of which will need a treatment that includes radiotherapy. Education is central: the radiotherapy team is composed of highly skilled healthcare professionals, dealing with the delivery of radiotherapy, the care and the management of the patients.